Recommendation and Acceptance of Counselling for Familial Cancer Risk in Newly Diagnosed Breast Cancer Cases
- PMID: 35702497
- PMCID: PMC9149417
- DOI: 10.1159/000517021
Recommendation and Acceptance of Counselling for Familial Cancer Risk in Newly Diagnosed Breast Cancer Cases
Abstract
Background: In clinical routine, not every patient who is offered genetic counselling and diagnostics in order to investigate a familial cancer risk predisposition opts for it. Little is known about acceptance of counselling and testing in newly diagnosed breast cancer cases in Germany.
Methods: All primary breast cancer cases and patients with DCIS (ductal carcinoma in situ) treated at the University Hospital of Dresden between 2016 and 2019 were included. The number of tumor board recommendations for genetic counselling on the basis of the GC-HBOC risk criteria was recorded. Acceptance was analyzed by number of cases with counselling in the GC-HBOC-Center Dresden.
Results: Of 996 primary breast cancer and DCIS cases, 262 (26.3%) were eligible for genetic counselling. Recommendation for genetic counselling was accepted by 64.1% (168/262). Of these 90.5% (152/168) opted for molecular genetic analysis. The acceptance rate for counselling increased between 2016 and 2019 from 58.3 to 72.6%. Altogether, 20.4% (31/152) patients were found to carry a pathogenic variant in the breast cancer genes BRCA1 or BRCA2.
Conclusion: Acceptance of recommendation is increasing as clinical consequences augment. Optimization in providing information about hereditary cancer risk and in accessibility of counselling and testing is required to further improve acceptance of recommendation.
Keywords: Acceptance; Breast cancer; Counselling; Genetic; Recommendation.
Copyright © 2021 by S. Karger AG, Basel.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
Similar articles
-
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.Oncologist. 1996;1(5):326-330. Oncologist. 1996. PMID: 10388011
-
"It wasn't just for me": Motivations and implications of genetic testing for women at a low risk of hereditary breast and ovarian cancer syndrome.Psychooncology. 2020 Aug;29(8):1303-1311. doi: 10.1002/pon.5436. Epub 2020 Jul 9. Psychooncology. 2020. PMID: 32497346
-
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.Gynecol Oncol. 2005 May;97(2):457-67. doi: 10.1016/j.ygyno.2005.01.039. Gynecol Oncol. 2005. PMID: 15863145
-
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.Fam Cancer. 2004;3(3-4):265-81. doi: 10.1007/s10689-004-9554-y. Fam Cancer. 2004. PMID: 15516851 Review.
-
Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer.Breast Care (Basel). 2022 Apr;17(2):199-207. doi: 10.1159/000516376. Epub 2021 Jul 19. Breast Care (Basel). 2022. PMID: 35702495 Free PMC article. Review.
Cited by
-
Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients.Breast Cancer Res Treat. 2023 Jun;199(2):363-370. doi: 10.1007/s10549-023-06909-z. Epub 2023 Mar 29. Breast Cancer Res Treat. 2023. PMID: 36988750
References
-
- Katz SJ, Kurian AW, Morrow M. Treatment Decision Making and Genetic Testing for Breast Cancer: Mainstreaming Mutations. JAMA. 2015;314((10)):997–8. - PubMed
-
- Hafertepen L, Pastorino A, Morman N, Snow J, Halaharvi D, Byrne L, et al. Barriers to genetic testing in newly diagnosed breast cancer patients: Do surgeons limit testing? Am J Surg. 2017;214((1)):105–10. - PubMed
-
- Rhiem K, Bücker-Nott HJ, Hellmich M, Fischer H, Ataseven B, Dittmer-Grabowski C, et al. Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort. Breast J. 2019;25((3)):455–60. - PubMed
-
- Menko FH, Ter Stege JA, van der Kolk LE, Jeanson KN, Schats W, Moha DA, et al. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice. Fam Cancer. 2019;18((1)):127–35. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous